Vaccination of dogs against heterologous Babesia canis infection using antigens from culture supernatants.
Soluble parasite antigens (SPA) from European Babesia canis can be used to protect dogs against a homologous but not heterologous challenge infection. In this study it is shown that when dogs are vaccinated with a mixture of SPA from both, a European B. canis isolate and a South African Babesia rossi isolate, protective immunity against heterologous B. canis infection is induced. Three groups of five beagle dogs each were vaccinated twice with graded doses of SPA derived from in vitro cultures of B. canis and B. rossi, with a 3-week interval. Saponin was used as adjuvant. Three weeks after booster vaccination immunological responsiveness against heterologous B. canis antigen was measured by seroconversion against infected erythrocytes and lymphocyte transformation using SPA. Upon vaccination dogs produced antibodies against infected erythrocytes and lymphoblastogenic responses against SPA in a dose-dependent manner. Dogs were then challenged with heterologous B. canis parasites. Dogs appeared to be protected against challenge infection, which was reflected in less severe decrease of packed cell volume (PCV) and reduced clinical signs. The level of protection to clinical signs (but not excessive PCV drop) was related to the level of SPA in plasma and spleen size, and not related to peripheral parasitaemia. The results suggest that vaccination with this bivalent vaccine primes T-helper cells that recognise common epitopes on SPA from an antigenically distinct B. canis isolate. These cells provide the essential Th signal to mount an effective and timely antibody response against SPA and parasites or parasitised erythrocytes, which prevents the further development of clinical babesiosis.
Schetters
T P
TP
Parasitology R&D Department, Intervet International B.V., P.O. Box 315830, AA Boxmeer, The Netherlands. theo.schetters@intervet.com
Kleuskens
J A
JA
Scholtes
N C
NC
Gorenflot
A
A
Moubri
K
K
Vermeulen
A N
AN
D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000276:immunology*; D001403:Babesia / Q000276:immunology*; D001404:Babesiosis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D004283:Dog Diseases / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D004285:Dogs; D004306:Dose-Response Relationship, Immunologic; D004912:Erythrocytes / Q000276:immunology / Q000469:parasitology; D006400:Hematocrit / Q000662:veterinary; D007117:Immunization, Secondary; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D018512:Parasitemia / Q000276:immunology / Q000662:veterinary; D016052:Protozoan Vaccines / Q000276:immunology*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016052:Protozoan Vaccines